Article
Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer.
Oncogene - 1 Aug 2026
Konecny Tomas, Zadirako Nate, Grigoryan Arpine, Tamazyan Melina, Mnatsakanyan Sveta, Stepanyan Luiza, Loeffler-Wirth Henry, Bourdelais Sean, Mednick Gabriel, Delepine Chloe, Chand Dhan, Binder Hans
Abstract excerpt
Conventional immune checkpoint inhibitors (ICIs) remain largely ineffective in microsatellite-stable metastatic colorectal cancer (MSS mCRC), where low tumor immunogenicity and molecular heterogeneity across metastatic sites underpin therapeutic resistance. We present a comprehensive transcriptomics analysis of metastatic and primary tumor biopsies from MSS mCRC patients treated with botensilimab (BOT;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
